Introduction
ETV6, a member of the ETS family of transcription factors, was initially identi®ed as a fusion partner gene of platelet derived growth factor receptor b (PDGFRb) in a chronic myelomonocytic leukemia with a t(5;12)(q33;p13) translocation (Golub et al., 1994) . ETV6 has since been determined to have several other fusion partners in a variety of human leukemias. To date 41 chromosomal bands have been demonstrated to be involved in ETV6 translocations (Odero et al., 2001) . The ETV6 fusion partners in eleven of these translocations have been determined, and several are known to be tyrosine kinases, including PDGFRB, ABL, JAK2 and NTRK3 (Golub et al., 1994 Knezevich et al., 1998; Lacronique et al., 1997) . ABL is known to be involved as a fusion partner in other oncogenes, such as Gag/ABL and BCR/ABL. ABL oncoproteins (BCR/ABL and ETV6/ABL), and other ETV6/TK fusion proteins (ETV6/PDGFRB, ETV6/ JAK2 and ETV6/NTRK3) transform growth-factordependent hematopoietic cell lines to factor-independence or transform ®broblast cell lines to anchorage independence (Carroll et al., 1996; Golub et al., 1996; Lugo and Witte, 1989; Schwaller et al., 1998; Wai et al., 2000) .
Recently, we and others identi®ed in leukemias a novel ETV6 fusion transcript in which ETV6 is fused to sequences of the ARG protein tyrosine kinase (ARG). Our laboratory detected the ETV6/ARG fusion transcript in an AML-M3 leukemia cell line (HT93A) with t(1;12)(q25;p13) and t(15;17)(q12;q21) translocations (Iijima et al., 2000) , and other groups found this fusion transcript in an AML-M4eo leukemia patient with t(1;12)(q25;p13) and inv(16)(p13q12) translocations (Cazzaniga et al., 1999) , and a mature T-ALL cell line (MT ± ALL) with t(1;10;12)(q25;q23;p13) translocations (Griesinger F, personal communication) . ARG is a non-receptor tyrosine kinase that, together with c-ABL, forms the Abelson subfamily of mammalian tyrosine kinases (Kruh et al., 1990) . The ETV6/ARG translocation is the ®rst instance in which ARG has been implicated in human cancers. By contrast, c-ABL fusion proteins, such as BCR/ABL and ETV6/ABL in humans and Gag/ABL in mice, are well-established oncogenes in leukemias and lymphomas, respectively (Andreasson et al., 1997; Golub et al., 1996; the prominent role that ABL oncogenes play in human malignancies, the absence of previous evidence implicating ARG in human cancers is perhaps somewhat surprising in that ARG and c-ABL share a striking degree of structural resemblance (Kruh et al., 1990) . Both are composed of SH2, SH3 and tyrosine kinase domains, and large carboxyl-terminal domains that constitute about half the length of the proteins. The SH2, SH3 and tyrosine kinase domains are highly conserved, sharing 90 ± 95% identity, whereas the Cterminal domains are less similar, sharing only 29% identity. Nevertheless, certain functional motifs within the c-ABL C-terminal domain, such as SH3 binding sites, are conserved in an analogous position in ARG .
While the ETV6/ARG fusion gene has now been detected in three independent human leukemias, its in vitro transforming activity has not been determined and its contribution to the etiology of these tumors is therefore unknown. This question is of particular interest in that each of the leukemias in which the ETV6/ARG transcript has been identi®ed harbor other translocations in addition to the ETV6/ARG translocation. Moreover, previous in vitro studies of the transforming activity of ARG indicate that its oncogenic activity is low compared to c-ABL. For example, by contrast with the robust transforming activity of the Gag/ABL oncogene, an engineered Gag/ ARG fusion protein lacks transforming activity . Thus it is possible that in the leukemias in which the ETV6/ARG fusion protein has been identi®ed, other translocations may play determinative oncogenic roles, as opposed to ETV6/ ARG. In the present study we sought to directly address this question by determining whether the ETV6/ARG fusion protein has in vitro transforming activity. In so doing it is demonstrated that ETV6/ ARG not only has the facility to transform Ba/F3 cells to factor independence, but that it also has the capacity to transform Rat-1 cells. In addition, it is shown that ETV6/ARG participates in some of the same pathways that have been implicated in signaling by ETV6/ABL oncogene. Together these observations suggest that ETV6/ARG contribute to the etiology of the human leukemias in which it has been detected and demonstrate for the ®rst time that ARG can undergo oncogenic activation in human tumors.
Results

ETV6/ARG-AL transforms Ba/F3 cells to IL3-independent growth
We previously identi®ed four types of ETV6/ARG transcripts in HT93A cells (Iijima et al., 2000) . These structures of these four fusion proteins, and the ETV6 and ARG exons from which they are derived, are shown schematically in Figure 1 . In two of the fusion proteins sequences from ®ve 5' ETV6 exons are spliced to either the ARG second or third exon (ETV6/ARG-AL and ETV6/ARG-AS, respectively). The complete ETV6 HLH domain is therefore present in each of these two fusion proteins. In addition, almost all of the ARG domains, including its SH3, SH2, tyrosine kinase and C-terminal domains, is present in the fusion proteins. However, 52 and 73 N-terminal ARG residues, respectively, are not present in ETV6/ARG-AL and ETV6/ARG-AS. In two other fusion proteins, ETV6 sequences derived from exons 3, 4 and 5 were spliced to the same two ARG exons described above, to generate ETV6/ARG-BL and ETV6/ARG-BS. In the latter two transcripts the HLH domain is incomplete as a result of usage of the alternative (IB) initiation codon located within exon 3.
The in vitro transforming activity of ETV6/ARG was examined by investigating its eects upon growth of Ba/F3 cells. This murine hematopoietic cell line is IL3-dependent, and can be employed to examine transforming activity by assessing the capacity of expressed proteins to render it growth factor independent (Carroll et al., 1996; Golub et al., 1996; Schwaller et al., 1998) . Ba/F3 cells were electroporated with expression vectors for each of the four ETV6/ARG cDNAs. As positive and negative controls, Ba/F3 cells were also electroporated with ETV6/ABL expression vector, which is known to transform Ba/F3 cells Okuda et al., 1996) , and with the parental pcDNA3 vector, respectively. G418-resistant colonies that expressed each of the ETV6/ARG proteins were isolated. Figure 2a shows the detection of ETV6/ARG fusion proteins in representative G418 selected cell lines. ETV6/ARG fusion proteins of 160*165 kD (AL and AS) and 150*155 kD (BL and BS), as well as the endogenous 145 kD ARG protein, were readily detected. The ETV6/ARG fusion proteins were expressed at comparable levels, and their apparent molecular weights were in good agreement with the calculated molecular weights of 162 kD, 160 kD, 152 kD and 150 kD for AL, AS, BL and BS, respectively. By contrast only the endogenous 145 kD ARG protein was detected in G418-selected cells electroporated with parental vector (Figure 2a ). Immunoblot analysis also revealed that ETV6/ABL was well expressed (data not shown).
To assess the transforming activities of the fusion proteins, the capacity of the ETV6/ARG-expressing cell lines to grow in IL3-free medium was analysed. From these experiment it was determined that of the four types of ETV6/ARG fusion proteins only ETV6/ ARG-AL has potent transforming activity, in that only Ba/F3 cells expressing this speci®c ARG fusion protein exhibited sustained growth in IL3-free medium. By contrast, Ba/F3 cells in which the other three ARG fusion proteins were expressed did not survive in IL3-free medium.
To more precisely assess the transforming activities of the ETV6/ARG fusion proteins, the capacity of the four cell lines to grow in a wide range of IL3 concentrations was determined. These experiments con®rmed the ability of ETV6/ARG-AL to promote factor independent growth, but also revealed that ETV6/ARG-AS was capable of conferring a growth advantage, albeit insucient to render cells completely factor independent. Figure 2b shows a comparison of the growth curves for Ba/F3 cells expressing the ETV6/ ARG fusion proteins with those of ETV6/ABLexpressing cells and control Ba/F3 cells. Three days after being transferred from medium supplemented with 1 ng/ml IL3 to IL3-depleted medium, the ETV6/ ARG-AL cell line exhibited a reduction in growth of no more than 22% at IL3 concentrations as low as 1610 79 ng/ml. This degree of growth was only modestly reduced compared to that of ETV6/ABLexpressing cells, whose growth was completely unaected by reduced IL3 concentrations. By comparison, control Ba/F3 cells and ETV6/ARG-BS and ETV6/ARG-BL-expressing cells exhibited dramatically impaired growth in IL3 concentrations of 0.1 ng/ml, and almost no growth at lower concentrations. ETV6/ ARG-AS-expressing cells exhibited a growth curve that was intermediate between ETV6/ARG-AL-expressing cells and control Ba/F3 cells.
One possible mechanism by which the ETV6/ARG-AL fusion protein could facilitate the growth of Ba/F3 cells is by stimulating IL3 production. To rule out this potential mechanism, the growth of control Ba/F3 cells in conditioned media obtained from ETV6/ARG-ALexpressing cells was analysed. These experiments revealed that conditioned media did not support the (Iijima et al., 2000) and their predicted encoded proteins. ETV6 has alternative ®rst exons, denoted 1A and 1B. The 1A-formed ETV6/ARG encodes a complete HLH domain, where the 1B-formed ETV6/ARG encodes a truncated HLH domain, as a result of usage of the alternative translation start site within exon 3. Two ARG splice variants occur in the ETV6/ARG transcripts (closed vertical arrow). One type of fusion includes ARG exon 2 (ARG nt 362) and another type begins with ARG exon 3 (ARG nt 425). The former fusion contains residues 53 ± 1183 of ARG, whereas the latter fusion contains residues 74 ± 1183 of ARG. The ETV6 junction in all transcripts occurs at nt 1033. All four fusion proteins are in-frame. The intron-exon junction of ARG was determined using the htgs-database of Blast server (NCBI). ETV6 exons are shaded and ARG exons are shown in black. The indicated protein domains are: HLH, helix loop helix; SH3-2, SH3 and SH2 domains; PTK, protein tyrosine kinase domain; CTD, C-terminal domain. Number of amino acid residues in each fusion protein are: AL=1471, AS=1450, BL=1383, BS=1362 ETV6/ARG is an oncoprotein Y Iijima et al growth of control Ba/F3 cells (data not shown), indicating that ETV6/ARG-AL does not confer factor independent growth by an autocrine mechanism involving IL3 or other growth factors.
ETV6/ARG-AL confers anchorage independent growth to Rat-1 cells
To further explore the transforming activity of ETV6/ ARG fusion proteins, it was next determined whether their expression has the facility to confer anchorage independent growth to Rat-1 ®broblast cells. From these experiments it was determined that ETV6/ARG-AL, but not the other ETV6/ARG fusion proteins, is capable of promoting anchorage-independent growth. Cell lines expressing the ETV6/ARG fusion proteins were obtained by transfecting Rat-1 cells with the ETV6/ARG expression vectors, or parental plasmid, and selection in G418-containing medium. G418-resistant colonies in which the fusion proteins were expressed were identi®ed by immunoblot analysis (Figure 3) . To serve as a positive control in this assay Rat-1 cells were transfected with ETV6/ABL expression vector. The capacity of the resulting cell lines to form colonies in soft agar is summarized in Table 1 . After two weeks of growth, numerous macroscopic colonies were observed for ETV6/ABL and ETV6/ ARG-AL expressing Rat-1 cells (Table 1 and Figure  4 ). By comparison, signi®cant numbers of soft agar colonies were not detected for the other three ETV6/ ARG fusion proteins, or for parental vector-transfected cells. Thus, the transforming properties of the four constructs expressed in Rat-1 cells were in good agreement with their ability to transform BaF3 cells to factor independence.
ETV6/ARG induces enhanced levels of tyrosine-phosphorylated cellular proteins
Cardinal biochemical features associated with expression of ABL oncogenes are increased levels of tyrosine phosphorylated cellular proteins and in vivo phosphorylation of the ABL fusion proteins (Okuda et al., 1996) . Whether ETV6/ARG fusion proteins also possess these properties was examined by ®rst analysing the presence of phosphotyrosine-containing proteins in the Ba/F3 cell lines in which the recombinant proteins were expressed. Figure 5a shows a representative anti-phosphotyrosine immunoblot of lysates prepared from Ba/F3 cells expressing the four ETV6/ARG proteins. Markedly elevated levels of tyrosine phosphorylated proteins were detected in ETV6/ARG-AL expressing cells, consistent with its robust transforming activity. By contrast, elevated levels of tyrosine phosphorylated proteins were not observed for the other ETV6/ARG-expressing cells. The levels of phosphotyrosine containing proteins in the ETV6/ ARG-AL expressing cells were roughly comparable to the levels observed in ETV6/ABL-expressing Ba/F3 cells. Prominent tyrosine-phosphorylated proteins of 120 kD, 85 kD, 66 kD and 36 kD were detected in ETV6/ABL-expressing cells. Each of these proteins was also observed in the ETV6/ARG-AL-expressing cells, although the 66 kD and 52 kD species were signi®-cantly reduced compared to the ERV6-ABL expressing cells. In addition to these protein species, the presence in ETV6/ARG-AL and ETV6/ARG-AS expressing cells of *160 kD proteins suggested that these two fusion proteins possessed in vivo tyrosine phosphotyrosine.
To directly determine whether ETV6/ARG-AL and ETV6/ARG-AS possess in vivo phosphotyrosine, the fusion proteins were immunoprecipitated by the use of anti-FLAG antibody, and then analysed by immunoblotting with anti-phosphotyrosine antibody. Figure 5b shows that bands corresponding to the expected sizes of ETV6/ARG-AL and ETV6/ARG-AS were observed, indicating that the fusion proteins were indeed tyrosine phosphorylated. (The 150 kD ETV6/ABL protein was also detected in the positive control). By contrast, phosphotyrosine was not detected for the ETV6/ARG BL and BS proteins. Thus, the levels of cellular phosphoproteins as well as the in vivo phosphotyrosine content of the ETV6/ARG fusion proteins were proportionate to their growth promoting properties.
Tyrosine phosphorylation of PI3K, SHC, ras-GAP and CRK-L by ETV6/ARG
To gain further insight into the mechanism by which ETV6/ARG transforms cells, we next sought to identify signaling pathways activated by this oncogene. Knowing that PI3K, SHC, ras-GAP and CRK-L are ) expressing the indicated fusion proteins, or parental plasmid-transfected cells, were plated in quadruplicate in 0.36% soft agar for 2 weeks and macroscopic colonies (Figure 4) were enumerated. Average values and standard deviations are shown Figure 4 Soft Agar colonies formed by Rat-1 cells expressing ETV6/ARG-AL. Soft agar assays were performed as described in Table 1 (Okuda et al., 1996) , and having detected tyrosine phosphorylated proteins whose sizes approximated the molecular weights of these proteins (85 kD, 45 kD, 65 kD, 120 kD and 36 kD, respectively) in anti-phosphotyrosine immunoblots of both lysates prepared from ETV6/ARG-expressing cells (Figure 5a ) and, with the exception of the 65 kD species, in ETV6/ARG pull down experiments (Figure 5b ), the possibility that these speci®c proteins are substrates of ETV6/ARG was directly examined. It was ®rst determined whether PI3K, SHC, ras-GAP and CRK-L were expressed at comparable levels in ETV6/ARG expressing Ba/F3 cells. As shown in Figure 6a , the expression levels of these signaling proteins were roughly comparable in Ba/F3 cells expressing the four ETV6/ARG fusion proteins, ETV6/ABL-expressing cells, and control cells. To determine whether ETV6/ARG interacts with PI3K, SHC, ras-GAP and CRK-L, anti-ETV6/ARG immunoprecipitates were analysed by immunoblotting with the corresponding antibodies. As shown in Figure 6b , each of these signaling proteins were detected in ETV6/ ARG-AL immunoprecipitates at levels comparable to those observed with ETV6/ABL immunoprecipitates. Lower levels of interaction were detected for ETV6/ ARG-AS. By contrast, complexes were not detectable for the other ETV6/ARG fusion proteins. Consistent with the results of these experiments, PI3K, SHC, ras-GAP and CRK-L were determined to be phosphorylated on tyrosine in ETV6/ARG-AL-expressing cells at levels that approximated those observed in ETV6/ ABL-expressing cells, and at lower levels in ETV6/ ARG-AS-expressing cells (Figure 6c ). By comparison, corresponding phosphotyrosine signals were either undetectable or barely detectable in cells expressing ETV6/ARG-BL and ETV6/ARG-BS. The smallest band of SHC (46 kD) was not detected this time (Figure 6c ), which were sometimes detected, although this reason is unknown.
Discussion
ABL fusion proteins, such as BCR/ABL and ETV6/ ABL, are well-established as oncoproteins in human leukemias Okuda et al., 1996; Wang, 1993) . Recently ARG, the only other member of the mammalian ABL family, has been implicated in human cancer by virtue of the identi®cation of ETV6/ ARG fusion transcripts in three human leukemias (Cazzaniga et al., 1999; Iijima et al., 2000; Griesinger F, personal communication) . In this report it was determined whether the fusion protein encoded by ETV6/ARG has oncogenic activity. The demonstration here that ETV6/ARG has the facility to transform both Ba/F3 cells and Rat-1 cells establishes it as an oncoprotein and suggests that the translocation from which it is derived has important biological consequences for the leukemias in which it has been identi®ed.
Insights pertaining to the mechanism by which ARG undergoes oncogenic activation, as well as the mechanism by which it transforms cells, were aorded by examination of the activities of the four fusion proteins encoded by ETV6/ARG transcripts identi®ed in HT93A cells. Of particular note was the determination that the capacity of ETV6/ARG fusion proteins to support IL3-independent growth of Ba/F3 cells strictly correlates with both the in vivo phosphotyrosine content of the fusion proteins and the levels of intracellular tyrosine phosphorylated proteins. These ®ndings provide strong evidence to support the idea that the oncogenic activity of ETV6/ARG-AL (as well as the weaker growth-promoting activity of ETV6/ ARG-AS) is a consequence of the acquisition of constitutive kinase activity, as is the case for ABL oncogenes (Okuda et al., 1996) . The fact that ARG-IB is not phosphorylated on tyrosine residues in vivo (GD Kruh and TH Mysliwiec, unpublished observations), by comparison with ETV6/ARG-AL and ETV6/ARG-AS, is also in agreement with this idea. In addition, these results also support the notion that ETV6/ARG is activated by a molecular mechanism that resembles that proposed for human ABL oncoproteins. Oligomerization of BCR/ABL and ETV6/ABL, directed by BCR and ETV6 sequences, respectively, is thought to be important for their constitutive activities McWhirter et al., 1993) . In the case of ETV6/ ABL, the HLH motif has been determined to be the oligomerization site . The inability of ETV6/ARG proteins that have markedly truncated HLH domains (BL and BS forms) to support any degree of IL3-independent growth or to exhibit in vivo kinase activity, by contrast with those that have complete domains (AL and AS forms) and possess these activities, suggests that HLH-mediated oligomerization may also be critical for the activation of ETV6/ ARG fusion proteins.
However, the absence of detectable oncogenic activity and reduced in vivo kinase activity of ETV6/ ARG-AS, by comparison with ETV6/ARG-AL, is not likely to be a consequence of dierences in HLHmediated oligomerization in that both of these proteins have identical ETV6 sequences. Instead, the structure of ETV6/ARG-AL diers from ETV6/ARG-AS by the presence in the former protein of 21 N-terminal ARG amino acids that are absent in ETV6/ARG-AS. In view of this modest dierence in structure, the weaker activity of ETV6/ARG-AS is perhaps surprising. Firstly, the ETV6/ARG fusion junction in ETV6/ ARG-AS occurs at a position in ARG that is analogous to the ABL junction found in both ETV6/ ABL and BCR/ABL McWhirter et al., 1993) . Hence, ARG sequences analogous to the entire ABL segment present in the latter oncoproteins are also possessed by ETV6/ARG-AS. Secondly, the additional 21 amino acids present in ETV6/ARG-AL are not known to constitute a functional domain in ARG. Indeed, all of the known ARG functional domains, with the exception of the N-terminal myristoylization site are present in all four ETV6/ARG proteins. These include, from N-terminus to C-terminus, a PxxP motif binding site (SH3 domain), a phosphotyrosine binding site (SH2 domain), a tyrosine kinase domain, SH3 binding sites (PxxP motifs) and a conserved C-terminal sequence that is able to bind RNA polymerase (Baskaran et al., 1997; Kruh et al., 1990; . The mechanism by which the 21-amino acid ARG segment contributes to the activity of the AL fusion protein remains to be established.
In considering the relative activities of the AL and AS forms, it should be kept in mind that while the latter fusion protein did not exhibit oncogenic activity in the experimental conditions employed in the present study, it did display some degree of growth-promoting properties in Ba/F3 cells (Figure 2b) . Therefore it is possible that it may contribute to the transformed phenotype of the malignant cells in which it has been identi®ed. This possibility is of interest because both the ETV6/ARG-AL and ETV6/ARG-AS forms were detected in each of the three characterizations of cells harboring the ETV6/ARG translocation. (To date the BL and BS forms have only been detected in HT93A cells and the analysis described herein suggests that these splice variants are unlikely to be biologically signi®cant). It is also important to emphasize that while our experiments indicate that ETV6/ARG has in vitro oncogenic activity, its ability to fully transform human hematopoietic cells in vivo in the absence of other contributing factors is unknown. This consideration is particularly relevant in view of the observation that in both of the reported cases of ETV6/ARGassociated malignancies other translocations are also present. HT93A cells were established from a patient with AML-M3 and harbor the t(15;17)(q22;q11.2) translocation associated with this disease, and the other reported ETV6/ARG translocation was identi®ed in a patient with AML-M4 with eosinophilia and inv(16).
ARG and c-ABL share a high degree of structural resemblance within their SH2, SH3 and TK domains (90 ± 95% identity). However, their large C-terminal domains are less similar, (29% identity) and this distinction accounts for the inability of ARG to be activated by fusion with Gag sequences , as occurs in the naturally occurring Gag/ ABL oncogene. In view of the distinct transforming properties suggested by the analysis of Gag/ARG and Gag/ABL fusion proteins, it was of interest to determine whether the biochemical mechanism by which ETV6/ARG transforms hematopoietic cells is similar to that of BCR/ABL and ETV6/ABL. As a ®rst step toward addressing this question, several previously ETV6/ARG is an oncoprotein Y Iijima et al described substrates of BCR/ABL and ETV6/ABL were examined in ETV6/ARG-expressing cells, including PI3K, SHC, ras-GAP and CRK-L. The ability of ETV6/ARG to phosphorylate and complex with each of these signaling molecules in vivo, and to do so at levels comparable to that observed in ETV6/ABLexpressing cells, indicate that there are indeed striking similarities in the pathways that are activated by these two oncoproteins. Further characterization of the signaling pathways associated with ETV6/ARG will provide a more detailed understanding of the dierences and similarities between its activity and that of ABL oncoproteins.
Materials and methods
Generation of ETV6/ARG cDNA constructs
Full-length ETV6/ARG cDNAs were constructed by splicing partial fragments spanning the ETV6/ARG junction to ARG sequences (Kruh et al., 1990 
Cell lines and transfections
Ba/F3 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1.0 ng/ml of recombinant IL3 (Kirin Inc., Tokyo, Japan) in a 5% CO 2 incubator at 378C. The cells were electroporated with pcDNA3/ETV6/ARG-constructs, pcDNA3-ETV6/ABL Figure 6 Analysis of signaling proteins co-immunoprecipitated with ETV6/ARG. (a) Detection of PI3K, SHC, ras-GAP and CRK-L. Proteins were immunoprecipitated from lysates (1 mg) using anti-PI3K, SHC, ras-GAP and CRK-L antibodies, followed by immunoblotting with same antibodies. (b) Analysis of complex formation with ETV6/ARG and ETV6/ABL. ETV6 fusion proteins were immunoprecipitated with anti-FLAG or anti-ABL antibodies and complex formation analysed by immunoblotting with anti-PI3K, SHC, ras-GAP and CRK-L antibodies. (c) Analysis of in vivo phosphotyrosine content of PI3K, SHC, ras-GAP and CRK-L. PI3K, SHC, ras-GAP and CRK-L were immunoprecipitated with the corresponding antibodies and subsequently immunoblotted with anti-phosphotyrosine antibody (Okuda et al., 1996) and parental pcDNA3, as follows: 1610 7 Ba/F3 cells were washed in phosphate-buered saline (PBS), incubated for 10 min on ice with 10 mg of plasmid DNA in PBS, and electroporated at 300 mV/960 mFD in a Bio-Rad apparatus. After a 10-min incubation on ice, the cells were suspended with 10 ml of IL3 supplemented medium and incubated for 24 h. The cells were then distributed into 96-well plates and selected in medium containing IL3 and 1 mg/ml G418 (GIBCO BRL, Gaithersburg, MD, USA) for two weeks. G418-resistant cells were then subcloned and expression of the full-length fusion transcripts was con®rmed by RT ± PCR and immunoblotting. ETV6/ABL and ETV6/ ARG-AL expressing cells were cultured in IL3-free RPMI medium. ETV6/ARG-AS, BL, BS-expressing cells, and parental vector electroporated cells were cultured in RPMI supplemented with 1 ng/ml IL3. All cells were starved (IL3-free) for 18 h before harvest.
MTT growth assays
5610
3 Ba/F3 cells per well were plated in quadruplicate in 96-well plates, in RPMI 1640 media supplemented with 10% FBS and various concentrations of IL3. After 72 h of growth, MTT reagent (Wako, Osaka, Japan) was added to each well. MTT results were enumerated as the percentage of the values measured when cells were grown 1 ng/ml IL3.
Soft agar colony assay
